

## Servier appoints Nicolas Lévy as Chief Scientist Rare Diseases

**Paris, May 6, 2022** – Servier, a global independent pharmaceutical group, today announced the appointment of Nicolas Lévy, MD, PhD., as Chief Scientist Rare Diseases, effective as of June 1<sup>st</sup>, 2022. Based in Suresnes, France, Nicolas Lévy will report directly to Ross Jeggo, Head of the Neuroscience and Immuno-inflammation Therapeutic Area.

Nicolas Lévy will take a leading role in ensuring the acceleration of Servier’s research and development pipeline of projects that are focused on small targeted populations of patients with rare and ultra-rare diseases. He will contribute to strengthen our translational medicine approach, optimizing the medico-scientific strategy of projects from late discovery stage into first-in-human studies and assessment of clinical activity. Nicolas Lévy will also be responsible for consolidating and enriching our ecosystems of academic and private partnerships to extend Servier’s innovation capabilities and accelerate time to market.

*“I am delighted to welcome Nicolas Lévy to our global R&D Division. Nicolas Lévy’s scientific and medical expertise in rare disease is deeply recognized at national and international levels and I am convinced he will bring extraordinary knowledge and experience to support our ambitions in this field,”* said Claude Bertrand, Executive Vice President of Research and Development at Servier.

*“I am honored that Nicolas Lévy has chosen to join the Neuroscience & Immuno-inflammation leadership team, where I am confident that he will actively and significantly contribute to our mission to bring new therapeutic solutions to patients affected by rare diseases and for whom there are so few treatment options currently available,”* said Ross Jeggo, Head of the Neuroscience and Immuno-inflammation Therapeutic Area.

Nicolas Lévy, MD, PhD, is a clinician and Professor of Human and Medical Genetics, who has been committed to patients affected with rare diseases for over 30 years. Before joining Servier, Nicolas Lévy was Head of the department of Medical Genetics (Timone Hospital – Marseille, France) and Head of the Marseille Medical Genetics Research Center. He also founded the Rare Diseases Foundation and promoted “academic-industrial” partnerships to accelerate therapeutic innovations. Nicolas Lévy has also founded several start-up biotech companies, illustrating his passion for drug discovery and his desire to transform his academic research into medicines. Throughout his career to date, Nicolas Lévy has actively promoted strong connections between patients, diagnosis and research, towards the development of innovative drugs with therapeutic impact in rare and ultra-rare diseases with unmet medical needs.



*"I am delighted to join Servier with the shared ambition to accelerate pipeline advancements from research to clinical stages and to get the opportunity to deliver new therapeutic solutions to patients. I am looking forward to being part of this journey with the teams and in such a dynamic, motivated and scientifically excellent environment," said Nicolas Lévy.*

---

#### **About Servier**

Servier is a global pharmaceutical group governed by a Foundation. With a strong international presence in 150 countries and a total revenue of 4.7 billion euros in 2021, Servier employs 21,800 people worldwide. Servier is an independent group that invests over 20% of its brand-name revenue in Research and Development every year. To accelerate therapeutic innovation for the benefit of patients, the Group is committed to open and collaborative innovation with academic partners, pharmaceutical groups, and biotech companies. It also integrates the patient's voice at the heart of its activities.

A leader in cardiology, the ambition of the Servier Group is to become a renowned and innovative player in oncology. Its growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology, neuroscience and immuno-inflammatory diseases. To promote access to healthcare for all, the Servier Group also offers a range of quality generic drugs covering most pathologies. More information: [servier.com](https://www.servier.com)

Follow us on social media:



**Servier press contact:** Sonia Marques: [presse@servier.com](mailto:presse@servier.com) – Tel. +33 (0)1 55 72 40 21 / +33 (0)7 84 28 76 13